Showing 2301-2310 of 9403 results for "".
Connective Tissue Disorders Update 2025: Dr. Vleugels
https://practicaldermatology.com/programs/practical-dermatology/connective-tissue-disorders-update-2025-dr-vleugels/32673/Ruth Ann Vleugels, MD, PhD, recaps her presentation, "Connective Tissue Disorders Update 2025" at Maui Derm 2025. Dr. Vleugels discussed a new therapeutic for systemic lupus, a new FDA-approved option for dermatomyositis, JAK inhibitors, and more.A Meeting for Treating the Whole Person
https://practicaldermatology.com/conferences/noah-worcester/a-meeting-for-treating-the-whole-person/57065/Stan Tolkachjov, MD, Scientific Program Co-chair for the Noah Worcester Dermatological Society’s 2026 Annual Meeting, explains what he and Co-chair David Wetter, MD, sought to accomplish with this year’s presentations.Going Off-Label
https://practicaldermatology.com/conferences/noah-worcester/going-off-label/57063/Francisca Kartono, DO, discusses her presentation, “Practical Pearls: Off-Label Topical and Systemic Strategies that Work,” from the Noah Worcester Dermatological Society’s 2026 Annual Meeting.A Case Presentation of Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37154/Alina Bridges, DO, Director of Dermatopathology & Associate Professor in the Department of Dermatology and Anatomic Pathology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, presents a case study involving a patient who had been on multiple treatments to present prurituDWTV Extra: Rocatinlimab Trials
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-rocatinlimab-trials/39044/Clinical investigator Emma Guttman-Yassky, MD, PhD, discusses two sets of data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. The phase 3 ROCKET-Ignite Trial evaluated the efficacy and safety of OX40-receptor targeting with rocatinlimab in moderate-to-severe aThe Impact of Clascoterone Topical Cream, 1%
https://practicaldermatology.com/issues/april-2025/the-impact-of-clascoterone-topical-cream-1/35605/Clascoterone topical cream, 1% (Winlevi, Sun Pharmaceuticals, Inc.) approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older.We've Got to Do Better
https://practicaldermatology.com/topics/practice-management/weve-got-to-do-better/20018/As a specialty, dermatology is doing more to address issues of diversity, equity, and inclusion, but Jeanine Downie, MD says there is more to do. She discusses issues such as dealing with microaggressions, increasing diversity in the workforce, and seeing the humanity in every patient.Elucidating the Inflammatory Cascade May Help to Turn Out the Lights in Psoriasis
https://practicaldermatology.com/topics/psoriasis/elucidating-the-inflammatory-cascade-may-help-to-turn-out-the-lights-in-psoriasis/19943/Understanding the science behind psoriasis pathogenesis has raised the bar in the management of disease. Watch the video to visualize the patient journey, their unmet needs, and aim to set higher standards in the psoriasis landscape.The Easy Es of Managing Eczema
https://practicaldermatology.com/topics/atopic-dermatitis/the-easy-es-of-managing-eczema/19978/Atopic dermatitis can have a profound effect on patients' lives—from associated comorbidities to sleep issues and more. Adam Friedman, MD says it’s essential to Educate patients regarding good skin care, manage Expectations, provide Enough appropriate medication, End misdiagnoses, and Engage assistaInside the Latest Edition, June 2021
https://practicaldermatology.com/topics/practice-management/inside-the-latest-edition-june-2021/19959/Go inside our issue on acne and rosacea to get tips on new acne treatments, management of maskne, and strategies to improve your bottom line!